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Introduction. The role of podoplanin (PDPN) in nasopharyngeal carcinoma (NPC) is still unknown. The aims of this study were
to investigate the expression and role of PDPN in NPC cells.Materials and Methods. Immunofluorescence staining and functional
tests were used to determine the effects of PDPN knockdown by siRNA in TW01 NPC cells. Microarray analysis was conducted
to identify genes regulated by PDPN. The molecular mechanism of PDPN on NPC cells was further determined by Ingenuity
Pathways Analysis (IPA). Results. PDPN was expressed in most TW01 NPC cells. PDPN knockdown by siRNA decreased NPC cell
proliferation, migration, and invasion. The microarray data showed 63 upregulated genes and 12 downregulated genes following
PDPN knockdown. The top 5 most upregulated genes analyzed by IPA were IFI27, IFI44L, IFI6, OAS1, and TRIM22, and the most
relevant pathway was the interferon signaling pathway. Conclusions. To the best of our knowledge, this is the first report to show
that knocking down PDPN leads to suppression of NPC cell proliferation, migration, and invasion. Our results suggest that PDPN
may serve as a potential chemotherapeutic target for NPC treatment in the future.
1. Introduction
Nasopharyngeal carcinoma (NPC) is a common malignancy
in South Asia but is rare in Western countries. Its annual
incidence in southern China is > 20 cases per 100,000 people.
The pathogenesis of NPC is related to genes, the Epstein-
Barr virus (EBV), environment, and diet [1–5]. Currently,
radiotherapy is the main method for treating NPC, and
chemotherapy is added in cases with advanced stages. The
five-year survival for early-stage NPC is quite high and
nearly 90%. However, the prognosis of late-stage NPC is still
unsatisfactory, with the 5-year overall survival rates ranging
from60% to 73% in the literature [6–8]. Similar tomany other
cancer types, local recurrence and distant metastases remain
the main causes of treatment failure in NPC patients [1–5].
Thus, identifying new molecular markers may provide a way
to improve the survival of these patients by developing a novel
targeted therapy.
Podoplanin (PDPN), a 36- to 43-kDa transmembrane
sialomucin-like glycoprotein, has three structural domains:
a highly O-glycosylated (𝛼2,3-sialic acid linked to galac-
tose) extracellular domain, a hydrophobic transmembrane
domain, and a short nine-amino-acid cytoplasmic tail [9].
It was given different names in several previous studies
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such as PA2.26 antigen, E11 antigen, gp38, T1a, and Aggrus
and was finally called “podoplanin” because of its expres-
sion on kidney podocytes with association in the flattening
of the podocyte foot [10]. The expression of PDPN has
been characterized in many normal tissues including kidney
podocytes, type-1 lung alveolar cells, basal keratinocytes,
synovial fibroblasts, and lymphatic endothelial cells, and it is
now widely used as a marker for lymphatic endothelial cells
and fibroblastic reticular cells in lymphoid organs [11].
PDPN was suggested to play an important role in the
development of several organs inmouse studies including the
formation of the lymphatic vasculature, lung morphogenesis,
and cardiac development. Several functions of PDPN have
been found [12]. Its induction of platelet aggregation via
interaction with the C-type lectin-like receptor 2 (CLEC-2)
in platelets was found to be related to the differentiation of
the lymphatic vasculature from the blood vascular system,
themaintenance of high endothelial venule integrity in lymph
nodes, and tumor-induced platelet aggregation [12]. Recently,
PDPNwas also found to be upregulated in a variety of tumors
such as vascular tumors, malignant mesothelioma, tumors
of the central nervous system (CNS), germ cell tumors, and
squamous cell carcinomas [13, 14]. Moreover, several studies
have revealed that PDPN is involved in the motility and
metastasis of tumor cells [13, 15–20]. However, its role in NPC
remains unclear.
To characterize the role of PDPN in NPC, we investigated
the expression of PDPN in NPC cell lines and several
functional studies were conducted in our study.
2. Materials and Methods
2.1. Cell Culture. The TW01 NPC cell line was kindly pro-
vided by Dr. Lin CT (Department of Pathology and Graduate
Institute of Pathology, College of Medicine, National Taiwan
University, Taiwan) [21, 22]. The cell line was derived from
primary nasopharyngeal tumors from Chinese patients with
de novo NPC. The NPC cell line was maintained in DMEM
with 10% FBS at 37∘C under 5% CO
2
.
2.2. siRNA Transfection. To knock down PDPN expression
in NPC cells, the cells were first seeded on chamber slides or
96-well plates for 24 hours and then transfected with various
concentrations of PDPN siRNA (Dharmacon, L-048117-01-
0005,CO,USA) with Lipofectamine 3000 (Life Technologies,
CA, USA) according to the instructions of the manufacturer.
PDPN expression was analyzed by immunofluorescence 48
hours after siRNA transfer.
2.3. Immunoﬂuorescence Staining of Cultured Cells. After the
cells plated on chamber slides were confluent, the adherent
cells were fixed for 20 minutes in 4% paraformaldehyde
(Electron Microscopy Sciences Corp., Hatfield, PA, USA)
at room temperature. Cells were then washed in PBS for 5
minutes three times, blocked in blocking buffer for 1 hour, and
then incubated with mouse anti-human D2-40 monoclonal
antibody (podoplanin; BioLegend, San Diego, CA, USA)
overnight at 4∘C. The D2-40 antibody was used as the
primary antibody at a dilution of 1:40. For visualization, the
secondary antibody, preabsorbed goat anti-mouse DyLight-
488 (Abcam plc, Cambridge, UK), was used at a dilution
of 1:500 at room temperature for 2 hours. Hoechst stain
(Molecular Probes, Thermo Fisher Scientific Inc., Waltham,
MA, USA) was used at a dilution of 1:10000 for 15 minutes
to stain nuclei. Cells were then mounted using antifade
fluorescent mounting media (DAKO, Carpinteria, CA, USA).
Images were then acquired under a fluorescence microscope
(Olympus Fluoview FV10i, USA) with Fluoview software
(Olympus, USA).
2.4. WST-1 Cell Viability Test. The viability of the exposed
cells was determined using the WST-1 cell proliferation
reagent kit (Roche, Penzberg, Germany) according to the
manufacturer’s instructions. 1× 104 cells/well were seeded in a
96-well microplate for 24 hours. Cells were washed with PBS
twice and exposed to the control or to various concentrations
of PDPN siRNA in a humidified atmosphere (37∘C and 5%
CO
2
) for 3 days. The cells were incubated with 10𝜇l WST-
1 cell proliferation reagent for 2 hours, followed by using a
microplate reader (Spectral Max 250) at 450 nm to measure
the optical density.
2.5.WoundHealingAssay. Cellswere plated in 48-well plates.
When the cells grew to full confluency, a wound was created
on the monolayer cells by scraping using a micropipette tip
after cells had been treated with control or PDPN siRNA for
24 hours.The speed of wound closure was compared between
the PDPN siRNA-treated groups and the control siRNA
group. After wound incision and 24 hours later, photographs
were taken under 100× magnification using phase contrast
microscopy.
2.6. Cell Invasion Assay. Cell invasion assay was using a
Transwell cell culture chamber (Millipore, Bedford, MA,
USA) as described previously [23]. Briefly, a 8-𝜇m pore size
polycarbonate filter was first coated with Matrigel, dried, and
then reconstituted at 37∘C with culture medium. 2 × 104 cells
in DMEM containing 10% FBS per chamber were added to
the upper chamber, whereas culture medium containing 20%
FBS was placed in the lower chamber. Then, 2 × 104 cells in
DMEM containing 10% FBS per chamber were added to the
upper chamber. After cells were incubated with control or
PDPN siRNA at 37∘C for 48 hours, cells that had invaded the
lower side of the filter were fixed in methanol, stained with
DAPI, and five fields per chamber were then counted under
a fluorescence microscope.
2.7. Microarray Hybridization and Analysis. RNA from the
NPC cells treated with 200 nM PDPN siRNA was amplified
and labeled with biotin using theOvation Biotin RNAAmpli-
fication and Labeling System (NuGEN, San Carlos, CA, USA)
according to the manufacturer’s procedure. The fragmented,
biotinylated cDNA was used for hybridization at 45∘C for 17
hours with Affymetrix HG-U133 Plus 2.0 GeneChip microar-
rays (Affymetrix, Santa Clara, CA) as described by the
manufacturer’s recommendations. We scanned and digitized
the hybridization signals using an Affymetrix 7G Gene Chip
Scanner and GCOS Version 1.4.0.036 software, respectively.
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Figure 1: Expression of PDPN in TW01 NPC cells. PDPN expression was found in most TW01 NPC cells (upper row). The expression of
PDPN decreased after cells were treated with PDPN siRNA (lower row). PDPN in green; Hoechst nuclear stain in blue.
The raw expression data for differential expression analysis
were normalized using the GCRMA package and the expres-
sion value for each probe was defined as the base 2 logarithm
of the intensity in the samples. The microarray data were
deposited in the GEO database (GEO accession number:
GSE128502).We then used Ingenuity Pathway Analysis (IPA)
to assign biological functions to genes and network analysis
using the Ingenuity Pathways Knowledge Base (Ingenuity
Systems, Inc., Redwood City, CA, USA).
2.8. Statistical Analysis. All experiments were carried out in
triplicate, and at least three independent experiments were
performed. The results are presented as the means ± SDs.
Statistical comparisons of multigroup data were analyzed
by ANOVA, followed by Sheffe’s post-test using SPSS 12.0
software (SPSS Inc. Chicago, IL). A value of p<0.05 indicated
statistical significance.
3. Results
Positive PDPN staining was observed in most TW01 NPC
cells. The expression of PDPN decreased after cells were
treated with PDPN siRNA (Figure 1). The WST-1 assay
revealed that NPC TW01 cell proliferation was suppressed
after cells were treated with PDPN siRNA (Figure 2). PDPN
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Figure 2: Function of PDPN in TW01 NPC cell proliferation.
The WST-1 assay revealed that TW01 NPC cell proliferation was
suppressed after cells were treated with PDPN siRNA. PDPN siRNA
reduced cell viability in a concentration-dependent manner. Data
are means ± SEs from three independent experiments. ∗p < 0. 05
compared with the vehicle control group by ANOVA.
siRNA reduced cell viability in a concentration-dependent
manner. The wound healing assay was used to observe
whether PDPN played a role in cell motility. Indeed, we
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Figure 3: Function of PDPN in TW01 NPC cell migration. More cells migrated to the denuded area of the wounds in the control group (left)
than in the cells transfected with 200 nM PDPN siRNA (middle) and 200 nM PDPN siRNA (right) 24 hours after the creation of the wound.
found that TW01 NPC cells transfected with 200 nM PDPN
siRNA showed decreased cell migration compared to that
of the control group (Figure 3). In addition, the Matrigel
invasion assays revealed that the invasion of TW01 NPC cells
decreased after the cells were transfected with 200 nM PDPN
siRNA for 48 hours (Figure 4).
To identify differentially expressed genes, the gene
expression profiles of the NPC cell lines treated with and
without 200 nM PDPN siRNA were compared. A total of 75
genes were differentially expressed by at least 2-fold, includ-
ing 63 upregulated and 12 downregulated genes. The data
were then analyzed using the functional analysis tool IPA.
The Ingenuity Pathways Knowledge Base, which includes
more than 49,000 datasets containing thousands of human,
mouse, and rat genes, is used to assign biological functions
to genes with IPA. The top 10 upregulated molecules, top 10
downregulated molecules, and top 5 transcription factors are
listed in Tables 1, 2, and 3, respectively. Table 4 lists the top 5
ingenuity canonical pathways involved in the effect of PDPN
Table 1: Top 10 upregulated molecules analyzed by IPA.
Rank Gene Expression value
1 IFI27 7.041
2 IFI44L 5.551
3 IFI6 5.029
4 OAS1 4.580
5 TRIM22 3.315
6 IFITM1 3.130
7 OAS2 3.069
8 STAT1 2.809
9 CMPK2 2.793
10 OAS3 2.771
siRNA on NPC cells, including interferon signaling, the
activation of IRF by cytosolic pattern recognition receptors,
the role of pattern recognition receptors in the recognition
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Figure 4: Function of PDPN in TW01 NPC cell invasion. Matrigel invasion assays of TW01 NPC cells in the control group and the PDPN
siRNA group.Migrating cell numbers were counted on the opposite surfaces of filtermembranes 48 hours after seeding. ∗p < 0.001 compared
with the vehicle control group by ANOVA.
Table 2: Top 10 downregulated molecules analyzed by IPA.
Rank Gene Expression value
1 PDPN -2.199
2 NALCN -1.249
3 TMTC4 -1.220
4 ZFP1 -1.138
5 LINC00973 -1.114
6 JPH3 -1.101
7 BOP1 -1.060
8 MMP12 -1.043
9 RGL3 -1.042
10 SMIM2-AS1 -1.024
of bacteria and viruses, role of PKR in interferon induction
and antiviral response, and the role of RIG1-like receptors
in antiviral innate immunity. The most highly rated network
analyzed by IPA is shown in Figure 5.
4. Discussion
PDPN is a unique mucin-type transmembrane sialoglyco-
protein that has been widely used as a lymphatic endothe-
lial marker. Recently, it was found to be overexpressed in
various cancers including lymphangioma, Kaposi sarcoma,
hemangioendothelioma, epithelioid mesothelioma, semi-
noma, hemangioblastoma, glioblastoma multiforme, oral
squamous cell carcinoma (OSCC), head and neck SCC, and
squamous nonsmall cell lung cancer [13, 14, 24, 25]. The
present study is the first to characterize PDPN expression in
an NPC cell line.
PDPN is expressed by aggressive tumors with high
invasive and metastatic potential [26]. Wicki et al. showed
that PDPN-expressing cells were found at the invasion front
in more than 80% human squamous cell carcinomas [15].
PDPN expression also predicted the prognosis of patients
with oral SCC treated with neoadjuvant chemoradiotherapy
[27]. In addition to its role in tumor cells, PDPN also
plays a role in cancer-associated fibroblasts. PDPN-positive
fibroblast infiltration significantly decreased overall survival,
disease-free survival, and progression-free survival in lung
6 BioMed Research International
Table 3: Top 5 upstream regulators analyzed by IPA.
Rank Gene p-value Predicted Activation
1 IFNL1 1.15E-61 Activated
2 IFNA2 1.24E-58 Activated
3 MAPK1 1.59E-42 Inhibited
4 Interferon alpha 1.78E-41 Activated
5 IRF7 2.50E-41 Activated
Table 4: Top 5 canonical pathways identified by IPA.
Rank Canonical Pathways p-value Overlap
1 Interferon Signaling 5.53E-16 27.8% (10/36)
2 Activation of IRF by Cytosolic Pattern Recognition Receptors 3.44E-07 10.0% (6/60)
3 Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 3.55E-07 5.5% (8/145)
4 Role of PKR in Interferon Induction and Antiviral Response 8.64E-04 7.5% (3/40)
5 Role of RIG1-like Receptors in Antiviral Innate Immunity 9.29E-04 7.3% (3/41)
Relationship
Relationship
Other
Transcription Regulator
Group/Complex
Enzyme
Complex
Figure 5:Themost highly rated network analyzedwith IPA.The genes shaded red are upregulated, and those shaded green are downregulated.
All shaded genes are statistically significant. A dotted line means an indirect interaction between the two gene products, and a solid line
represents a direct interaction.
cancer patients [28]. Katsumata et al. found that PDPN-
positive cancer-associated fibroblasts enriched at the outer
edge of breast tumors suppressed the proliferation of T cells
in a nitric oxide-dependent manner [29].
PDPN promotes cell migration by interacting with the
ezrin/radixin/moesin (ERM) protein family, which anchors
the actin cytoskeleton [15]. Its involvement in actin remod-
eling of the cytoskeleton of tumor cells promotes tumor cell
invasion by increasing cell motility and the formation of
filopodia-like membrane protrusions [14]. The interaction
between PDPN and CLEC-2 is postulated to regulate tumor
invasion and metastasis [16–20]. PDPN knockdown could
cause impaired cell spreading with reduced filopodia. In con-
trast, its overexpression could induce an increase in cellular
protrusions and stress fibers with extensive parallel bundles
[14]. Takeuchi et al. found that the overexpression of PDPN
inmalignant pleural mesothelioma cells expressing low levels
of PDPNenhanced cell motility, while knocking down PDPN
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in malignant pleural mesothelioma cells expressing high
levels of PDPN decreased cell motility. They proposed that
PDPN-stimulated motility was mediated by the activation
of the RhoA/ROCK pathway [30]. Another study suggested
that PDPN mediates cytoskeletal remodeling and invasion
via hierarchical crosstalk between PDPN, Cdc42, and MT1-
MMP in the invadopodia [14]. EGF-Src-Cas pathway is
another postulated mechanism through which PDPN is
involved in cell migration, which results in the progression
of oral SCC [31].
Ohta et al. revealed that TGF-𝛽 positively and negatively
regulated the expression of PDPN [32]. Mei et al. found that
ErbB3 binding protein-1 (Ebp1) served as a transcriptional
activator to drive PDPN expression and contributed to oral
tumorigenesis [33]. Tsuneki1 et al. found that PDPN-positive
odontogenic tumor cells were located within areas of PCNA-
positive cells and that integrin 𝛽1 was localized in the cell
membrane of PDPN-positive cells in the intercellular space,
whereas fibronectin and MMP-9 were deposited, indicating
its close association with extracellular matrix signaling [34].
They later demonstrated that PDPN collaborated with CD44
in cell adhesion by tethering oral SCC cells to the hyaluronan-
rich ECM to secondarily promote oral SCC cell proliferation
[35]. Cioca et al. showed that podoplanin had multiple
functions in HCC: tumorigenesis, lymphatic neovasculariza-
tion, and tumor invasion [36]. Miyashita el al. revealed that
the high clonal expansion capacity of podoplanin-positive
tumor-initiating cell populations was the result of reduced
cell death by podoplanin-mediated signaling. They proposed
that podoplanin activity may be a therapeutic target for the
treatment of squamous cell carcinomas [37].
In our study, the knockdown of PDPN repressed the
proliferation, migration, and invasion of NPC cells. We
further used microarray analysis followed by IPA analysis
to identify PDPN-regulated genes. Our IPA data revealed
the top 10 upregulated and top 10 downregulated molecules.
Besides PDPN, many of these molecules, such as IFI6, IFI27,
IFI44L, and BOP1, also have been reported to be associated
with carcinogenesis and treatment in other types of cancers.
IFI6 (interferon alpha inducible protein 6), which plays a
critical role in the regulation of apoptosis, is induced by
interferon. Another interferon alpha inducible protein, IFI27,
has been found to be upregulated in some cancers. Moreover,
IFI27 overexpression could induce epithelial-mesenchymal
transition and promote migration, invasion, tumorigenicity,
stemness, and drug resistance in ovarian cancer cells [38].
IFI44L (interferon induced protein 44 like) can affect cancer
stemness, metastasis, and drug resistance in hepatocellular
carcinoma (HCC). It is a novel tumor suppressor and an
important prognostic marker of HCC [39]. BOP1 (block of
proliferation 1) has been reported to play an oncogenic role
in HCC by promoting epithelial to mesenchymal transition
[40].
PDPN might be a potential target for antimetastatic
therapy. Ochoa-Alvarez et al. demonstrated that targeting
PDPNwith amonoclonal antibody (NZ-1) and lectin (MASL)
inhibited the migration of PDPN-expressing OSCC cells
at nanomolar concentrations and inhibited cell viability
at micromolar concentrations through caspase-independent
nonapoptotic necrosis [41]. It has been proposed that
tumor-related thrombosis, subsequent inflammation, and
inflammation-induced cachexia are related to the CLEC-
2-podoplanin interaction and that anti-podoplanin has the
potential to prevent tumor metastasis and progression in
cancer patients [42, 43]. In our study, we demonstrated
that the transfection of NPC cells with PDPN siRNA truly
decreased NPC cell proliferation and cell motility. It seems
that PDPN will be a promising target for antitumor therapy
in NPC in the future.
5. Conclusions
Our findings demonstrated PDPN expression in NPC and
its involvement in NPC cell proliferation, migration, and
invasion. PDPN has potential as a chemotherapeutic target
for NPC treatment in the future.
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